Maxim Group began coverage on shares of Cancer Genetics (NASDAQ:CGIX) in a note issued to investors on Thursday, MarketBeat.com reports. The firm set a “buy” rating and a $6.00 price target on the medical research company’s stock. Maxim Group’s price target points to a potential upside of 179.07% from the stock’s current price.

The analysts wrote, “As the paradigm in oncology shifts to immune therapy with CAR-T, PARPs, Checkpoints, and even BTK inhibitors attracting attention, we must not forget that it is the advances in diagnostics/theranostics and molecular profiling that enable guided therapy.””

Several other equities research analysts also recently weighed in on CGIX. ValuEngine downgraded Cancer Genetics from a “hold” rating to a “sell” rating in a report on Friday, September 1st. HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Cancer Genetics in a research report on Thursday, September 21st. Finally, Zacks Investment Research cut Cancer Genetics from a “hold” rating to a “sell” rating in a research report on Wednesday, October 4th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the stock. Cancer Genetics has an average rating of “Hold” and an average target price of $5.56.

Shares of Cancer Genetics (NASDAQ:CGIX) opened at $2.15 on Thursday. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.01 and a current ratio of 2.01. Cancer Genetics has a 1-year low of $1.30 and a 1-year high of $5.30.

Several hedge funds and other institutional investors have recently made changes to their positions in CGIX. Granahan Investment Management Inc. MA boosted its stake in Cancer Genetics by 26.3% in the third quarter. Granahan Investment Management Inc. MA now owns 237,431 shares of the medical research company’s stock valued at $641,000 after acquiring an additional 49,371 shares during the period. Vanguard Group Inc. increased its holdings in shares of Cancer Genetics by 61.9% in the second quarter. Vanguard Group Inc. now owns 516,785 shares of the medical research company’s stock valued at $2,041,000 after buying an additional 197,619 shares in the last quarter. Northern Trust Corp raised its stake in Cancer Genetics by 61.0% during the 2nd quarter. Northern Trust Corp now owns 32,122 shares of the medical research company’s stock valued at $127,000 after purchasing an additional 12,168 shares during the period. Thompson Davis & CO. Inc. raised its stake in Cancer Genetics by 5,465.0% during the 2nd quarter. Thompson Davis & CO. Inc. now owns 111,300 shares of the medical research company’s stock valued at $440,000 after purchasing an additional 109,300 shares during the period. Finally, KCG Holdings Inc. acquired a new stake in Cancer Genetics during the 1st quarter valued at $102,000. 12.71% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION NOTICE: This story was posted by American Banking News and is the sole property of of American Banking News. If you are accessing this story on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/07/maxim-group-reaffirms-buy-rating-for-cancer-genetics-cgix.html.

About Cancer Genetics

Cancer Genetics, Inc is a United States-based company, which is engaged in the field of personalized medicine. The Company offers diagnostic products and services that enable precision medicine in the field of oncology through molecular markers and diagnostics. The Company offers a range of laboratory services that provide genomic and biomarker information.

Receive News & Ratings for Cancer Genetics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cancer Genetics Inc and related companies with MarketBeat.com's FREE daily email newsletter.